IL201401A - N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects - Google Patents

N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects

Info

Publication number
IL201401A
IL201401A IL201401A IL20140109A IL201401A IL 201401 A IL201401 A IL 201401A IL 201401 A IL201401 A IL 201401A IL 20140109 A IL20140109 A IL 20140109A IL 201401 A IL201401 A IL 201401A
Authority
IL
Israel
Prior art keywords
oxide
dopamine receptor
cardiovascular side
improved cardiovascular
displaying improved
Prior art date
Application number
IL201401A
Other languages
English (en)
Hebrew (he)
Other versions
IL201401A0 (en
Original Assignee
Ivax Int Gmbh
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh, Nsab Af Neurosearch Sweden Ab filed Critical Ivax Int Gmbh
Publication of IL201401A0 publication Critical patent/IL201401A0/en
Publication of IL201401A publication Critical patent/IL201401A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL201401A 2007-04-12 2009-10-11 N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects IL201401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (2)

Publication Number Publication Date
IL201401A0 IL201401A0 (en) 2010-05-31
IL201401A true IL201401A (en) 2015-10-29

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201401A IL201401A (en) 2007-04-12 2009-10-11 N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects

Country Status (19)

Country Link
US (1) US9139525B2 (cg-RX-API-DMAC7.html)
EP (1) EP2146961B1 (cg-RX-API-DMAC7.html)
JP (1) JP5393654B2 (cg-RX-API-DMAC7.html)
CN (1) CN101711236B (cg-RX-API-DMAC7.html)
AU (1) AU2008239841B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810161A2 (cg-RX-API-DMAC7.html)
CA (1) CA2683719C (cg-RX-API-DMAC7.html)
CY (1) CY1115337T1 (cg-RX-API-DMAC7.html)
DK (1) DK2146961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2458592T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140380T1 (cg-RX-API-DMAC7.html)
IL (1) IL201401A (cg-RX-API-DMAC7.html)
MX (1) MX2009011020A (cg-RX-API-DMAC7.html)
NZ (1) NZ580856A (cg-RX-API-DMAC7.html)
PL (1) PL2146961T3 (cg-RX-API-DMAC7.html)
PT (1) PT2146961E (cg-RX-API-DMAC7.html)
RU (1) RU2470013C2 (cg-RX-API-DMAC7.html)
SI (1) SI2146961T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008127188A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2402713T3 (es) * 2008-11-24 2013-05-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Derivados de 3-fenilo-3-metoxipirrolidina como moduladores de la transmisión catecolaminérgica cortical
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH ハンチントン病を治療するための高用量プリドピジンの使用
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN110505902B (zh) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗脆性x综合征的应用
ES2938546T3 (es) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (cg-RX-API-DMAC7.html) 1962-10-10
CH481123A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ATE201669T1 (de) 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ATE253364T1 (de) 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
NZ552409A (en) 2004-06-08 2010-04-30 Nsab Af Neurosearch Sweden Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MXPA06013944A (es) * 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
SG169238A1 (en) * 2004-08-11 2011-03-30 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
DK1802573T3 (en) * 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
RU2394821C2 (ru) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-оксиды как пролекарства производных пиперазина и пиперидина
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP2009535374A (ja) * 2006-05-02 2009-10-01 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピリジルメチルピペラジンおよび−ピペリジン誘導体のn−オキサイド
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) * 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
CA2810092A1 (en) * 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US20130267552A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014052933A1 (en) * 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
MX2015003812A (es) * 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.

Also Published As

Publication number Publication date
JP5393654B2 (ja) 2014-01-22
CA2683719A1 (en) 2008-10-23
CA2683719C (en) 2015-07-14
SI2146961T1 (sl) 2014-08-29
EP2146961B1 (en) 2014-01-29
WO2008127188A1 (en) 2008-10-23
EP2146961A4 (en) 2011-08-03
DK2146961T3 (da) 2014-04-28
AU2008239841A1 (en) 2008-10-23
CN101711236B (zh) 2012-10-31
NZ580856A (en) 2011-11-25
CY1115337T1 (el) 2017-01-04
AU2008239841B2 (en) 2013-07-18
ES2458592T3 (es) 2014-05-06
RU2009141300A (ru) 2011-05-20
MX2009011020A (es) 2009-10-30
RU2470013C2 (ru) 2012-12-20
EP2146961A1 (en) 2010-01-27
IL201401A0 (en) 2010-05-31
CN101711236A (zh) 2010-05-19
HRP20140380T1 (hr) 2014-08-15
JP2010523651A (ja) 2010-07-15
PT2146961E (pt) 2014-04-30
US20100105736A1 (en) 2010-04-29
PL2146961T3 (pl) 2014-09-30
BRPI0810161A2 (pt) 2014-12-30
US9139525B2 (en) 2015-09-22

Similar Documents

Publication Publication Date Title
IL201401A0 (en) N - oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
IL201202A0 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
IL205176A0 (en) Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
IL210412A0 (en) Heterocyclic derivatives and uses thereof
EP2265731A4 (en) METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE
ZA201008611B (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
EP2188295A4 (en) PYRIDINE DERIVATIVES AND METHODS OF USE
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
ZA201004914B (en) Compositions and methods of detecting tiabs
PT2615085E (pt) Derivados piridilo como moduladores cftr
ZA201006475B (en) Heterocyclic derivatives
PL2110502T3 (pl) Zawias puszkowy
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
BRPI0919331A2 (pt) derivados de pirazolo piridina, composições farmacêuticas e métodos associados
PT2367815E (pt) Derivados de piridazinona
IL212636A0 (en) Pyridazinone derivatives
IL213570A (en) History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them
PL2280962T3 (pl) Pochodne pirydazynonowe
IL213346A0 (en) Dihydropyridone amides as p2x7 modulators
EP2081950A4 (en) EXPRESSION PROFILES ASSOCIATED WITH IRINOTECAN TREATMENT
IL213352A0 (en) Dihydropyridone amides as p2x7 modulators
EP2139891A4 (en) 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE
IL213417A0 (en) Dihydropyridone amides as p2x7 modulators
EP2285778A4 (en) NIKOTINAMIDDERIVATE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees